The biotech company Moderna injected a new dose of optimism into the fight against COVID-19 on Monday by announcing that its vaccine candidate had shown a success rate of 94.5% in clinical trials .The announcement, however, raises new questions about how a successful vaccine will be distributed to the public — how fast, how broadly and at what price?
Source: The Colossal Problem of Publicly Funded Vaccines in Private Hands | Portside
